The US Food and Drug Administration’s Oncology Center of Excellence will hand-select applications to enroll in its “Project Orbis” multi-national parallel review pilot program, with a focus on those that are expected to have a major impact on the standard of care – including “Breakthrough”-designated projects and novel treatments.
OCE announced the Orbis pilot at the same time it approved the first application in conjunction with Australian and Canadian...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?